Roth Capital raised the firm’s price target on Gain Therapeutics (GANX) to $10 from $6 and keeps a Buy rating on the shares. The firm says GT-02287 demonstrated blood-brain barrier penetration and triggered a reduction in GluSph levels in the Phase 1b study. This offers “direct mechanistic evidence” for GCase target engagement, the analyst tells investors in a research note. Roth cites the data for the target increase.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
- Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
- Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
- Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
- Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data